UK National Cancer Imaging Translational Accelerator (NCITA) establishes infrastructure for validation and adoption of cancer imaging biomarkers as decision-making tools in clinical trials and NHS practice. Researchers and medical experts from nine world-leading medical imaging centres across the UK come together to form an integrated infrastructure for standardising and validating cancer imaging biomarkers for clinical use.
Group of Professor Kristijan Ramadan has published an original scientific article in Nature Communications today. The article has the first report of a new autophagy receptor TEX264, which may be involved in tumours developing drug resistance.
Congratulations to Prof Kristijan Ramadan who has been awarded a three year research grant from Breast Cancer Now. The grant will support Dr. Abhay Narayan Singh who will explore new ways to use chemotherapy in order to improve the outcomes for women with breast cancer.
Tuesday 4 Feb 2020 is World Cancer Day (https://www.worldcancerday.org/).\r\n\r\nLed by the Union for International Cancer Control, the day aims to raise awareness and education about cancer.
The NIHR has invested \u00a334 million of funding into global health research projects to tackle epilepsy, infection-related cancers and severe stigmatising skin diseases in low- and middle-income countries (LMICs).
Kristijan Ramadan and his group published a new article in The EMBO Journal today. The article adds new detail to the story of how our cells repair damage to our DNA.
The Department of Oncology has signed up to collaborate with Crescendo Biologics Ltd (Crescendo), the drug developer of novel, targeted T cell enhancing therapeutics.
The new 7-year research collaboration with Janssen Research & Development, LLC (Janssen) will study patients at higher risk of developing certain types of blood cancers that arise from the immune system, such as chronic lymphocytic leukaemia and multiple myeloma, to identify markers that could be used to predict who will go on to develop symptomatic disease.
Research by the DNA Damage & Disease research group has for the first time observed molecular fibres that may hold together sections of broken DNA in mitosis.
Researchers in Oxford have found that an individual\u2019s immune system \u2013 and in particular the presence of T-cells amongst tumour cells - may play an important role in survival after surgery to remove pancreatic cancer.
The Department of Oncology is pleased to announce that Professor Amato J Giaccia has been appointed as the new Director of the MRC Oxford Institute for Radiation Oncology (OIRO).
Researchers in the Department of Oncology have secured funding to characterise an insulin-like growth factor (IGF) signature for early detection and risk reduction of cancer.
Scientists from the Department of Oncology have equipped a virus that kills carcinoma cells with a protein so it can also target and kill adjacent cells that are tricked into shielding the cancer from the immune system.
Greg Clark, UK Secretary of State for Business, Energy and Industrial Strategy (BEIS), will confirm today (Tuesday 6 November) that UK Research and Innovation will invest \u00a310million in the National Consortium of Intelligent Medical Imaging (NCIMI), to be led from Oxford University as part of the Industrial Strategy Challenge Fund.
![](\"https://www.oncology.ox.ac.uk/news/integrating-cancer-imaging-biomarker-clinical-research-across-the-uk/responsive_image?ratio=r16x9&scale=w760\")
\n \n \n\n\n